Crinetics Pharmaceuticals Announces Board and Executive Changes
Ticker: CRNX · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: CRNX
TL;DR
CRNX board shakeup and exec comp changes effective Feb 21.
AI Summary
Crinetics Pharmaceuticals, Inc. announced on February 21, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives. These changes are effective as of February 21, 2025.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategic direction or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.
Key Numbers
- 001-38583 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-3744114 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- February 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
Who departed from Crinetics Pharmaceuticals, Inc. as reported in this filing?
The filing reports the departure of "certain officers" and "certain directors" but does not name them specifically in the provided text.
What are the key items reported in this 8-K filing?
The filing reports the departure of directors or certain officers, election of directors, appointment of certain officers, regulation FD disclosure, and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 21, 2025.
What is the principal executive office address for Crinetics Pharmaceuticals, Inc.?
The principal executive offices are located at 6055 Lusk Boulevard, San Diego, California, 92121.
What is the SIC code for Crinetics Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Crinetics Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Crinetics Pharmaceuticals, Inc. (CRNX).